Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01089010 · ClinicalTrials.gov registry record · Phase 2
A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase 2 study, sponsored by Cytokinetics.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
NCT01089010 is a Phase 2 study that has completed, run by Cytokinetics. The registered enrollment target is 67 participants.
The verdict
NCT01089010, a Phase 2 study, has completed, sponsored by Cytokinetics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
Study Summary
The primary objective of this study is to demonstrate a pharmacodynamic effect of CK 2017357 on measures of skeletal muscle function or fatigability in patients with ALS.
Interventions
- DRUG Placebo
- DRUG 500 mg CK-2017357
- DRUG 250 mg CK-2017357
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2010-03 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01089010
The ClinicalTrials.gov registry entry for NCT01089010 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cytokinetics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01089010 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01089010 about?
NCT01089010 is a clinical study titled "A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)". The primary objective of this study is to demonstrate a pharmacodynamic effect of CK 2017357 on measures of skeletal muscle function or fatigability in patients with ALS.
What is the current status of trial NCT01089010?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2010-03. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01089010?
The interventions under investigation include: Placebo (DRUG), 500 mg CK-2017357 (DRUG), 250 mg CK-2017357 (DRUG).
Who is sponsoring clinical trial NCT01089010?
This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.